Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Rekha Kumar, about why the company was originally started, and how it wants to change how the healthcare system approaches weight management
As a selective GLP-1 receptor agonist, semaglutide activates receptors in the brain regions controlling appetite and satiety, particularly the hypothalamus and brainstem
Retatrutide (LY3437943) is a peptide developed by Eli Lilly that acts on three different metabolic receptors simultaneously: GLP-1 receptor GIP receptor Glucagon receptor This makes Retatrutide the first triple-agonist peptide to reach advanced Phase 3 clinical development
Liisa Tolvanen is specialist obesity registered dietitian, Karolinska Institutet, Sweden
What to Expect: Texture: Serum Consistency: Lightweight Scent: Fragrance Free Gently pat onto eye area using your ring finger
